Read More 2 minute read Pharma Industry News AstraZeneca’s Fasenra meets primary endpoint in MANDARA Phase 3 trial for EGPA AstraZeneca’s Fasenra met its primary endpoint in the MANDARA Phase III trial, offering a monthly treatment option for… byPallavi MadhirajuSeptember 11, 2023